Proof of concept evaluation of a novel breast cancer therapeutic

最近的研究表明，癌细胞表面上一种称为血管紧张素II I型受体（AT 1 R）的受体的过度活化，触发了在许多癌症相关过程中发挥作用的生物信号传导途径，包括肿瘤生长、血管生成、aTen Therapeutics正在开发一种新的治疗性抗体，可以靶向和阻断癌症-相关的信号转导介导的AT 1 R，以治疗乳腺癌。该项目是开发创新乳腺癌疗法的重要一步，有可能成为改善患者生活质量和持续时间的主要新药。

Recent research has suggested that the over activation of a receptor on the surface of cancer cells, called the angiotensin-II type I receptor (AT1R), triggers biological signalling pathways that play a role in many cancer-related processes including tumour growth, angiogenesis, drug resistance and metastasis.aTen Therapeutics is developing a novel therapeutic antibody that targets and blocks cancer-related signalling mediated by the AT1R in order to treat breast cancer. This project is a vital step in the development of an innovative breast cancer therapy with the potential to become a major new drug to improve the quality and duration of patients' lives.